Effect of Immediate Prior-Line Lenalidomide or Thalidomide Therapy on Response To Pomalidomide In Multiple Myeloma

被引：0
|
作者：
Hwa, Yi Lisa
Laumann, Kristina M.
LaPlant, Betsy R.
Buadi, Francis
Dingli, David
Dispenzieri, Angela
Gertz, Morie A.
Go, Ronald S.
Hayman, Suzanne R.
Kapoor, Prashant
Kumar, Shaji K.
Leung, Nelson
Lin, Yi
Lust, John A.
McCurdy, Arleigh
Mikhael, Joseph
Roy, Vivek
Russell, Stephen
Zeldenrust, Steven R.
Rajkumar, S. Vincent
Lacy, Martha Q.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1979.1979
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1979
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Treatment of multiple myeloma with immunomodulatory drugs - thalidomide, lenalidomide and pomalidomide
    Rzepecki, Piotr
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2009, 13 (05): : 265 - 275
  • [2] Thalidomide and lenalidomide in multiple myeloma
    Mazumder, Amitabha
    Jagannath, Sundar
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 (04) : 769 - 780
  • [3] Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
    Sonneveld, Pieter
    Zweegman, Sonja
    Cavo, Michele
    Nasserinejad, Kazem
    Broijl, Annemiek
    Troia, Rosella
    Pour, Ludek
    Croockewit, Sandra
    Corradini, Paolo
    Patriarca, Francesca
    Wu, Kalung
    Droogendijk, Jolanda
    Bos, Gerard
    Hajek, Roman
    Teresa Petrucci, Maria
    Ypma, Paula
    Zojer, Nicholas
    Minnema, Monique C.
    Boccadoro, Mario
    [J]. HEMASPHERE, 2022, 6 (10): : E786
  • [4] Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
    Zhu, Yuan Xiao
    Kortuem, K. Martin
    Stewart, A. Keith
    [J]. LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 683 - 687
  • [5] Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma
    Zou, Yandun
    Sheng, Zhixin
    Niu, Shaona
    Wang, Huijuan
    Yu, Jinming
    Xu, Jingbo
    [J]. LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2219 - 2225
  • [6] Thalidomide and lenalidomide in the treatment of multiple myeloma
    Kumar, Shaji
    Rajkumar, S. Vincent
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (11) : 1612 - 1622
  • [7] An audit of thromboprophylaxis for patients with myeloma on the immunomodulatory therapies: thalidomide, lenalidomide or pomalidomide
    Melly, M.
    Al-Talib, M.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 186 - 186
  • [8] Clinical Experience with Thalidomide and Lenalidomide in Multiple Myeloma
    Moehler, T.
    [J]. CURRENT CANCER DRUG TARGETS, 2012, 12 (04) : 372 - 390
  • [9] Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
    Guglielmelli, T.
    Bringhen, S.
    Rrodhe, S.
    Gay, F.
    Cavallo, F.
    Berruti, A.
    Montefusco, V.
    Piro, E.
    Benevolo, G.
    Petrucci, M. T.
    Caravita, T.
    Offidani, M.
    Corradini, P.
    Boccadoro, M.
    Saglio, G.
    Palumbo, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 (06) : 814 - 818
  • [10] Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma
    P Kapoor
    S Kumar
    S J Mandrekar
    K M Laumann
    A Dispenzieri
    M Q Lacy
    D Dingli
    M A Gertz
    R A Kyle
    P R Greipp
    S V Rajkumar
    T E Witzig
    [J]. Leukemia, 2011, 25 : 1195 - 1197
12345